1073 A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PRJ1–3024in subjects with advanced solid tumors - Yang Xu; Alexander Starodub; Cesar Perez; Yuping Li; Andrae Vandross; Jason Henry; Alexander I Spira; Xuebin Liao (Journal for ImmunoTherapy of Cancer, 2023)